A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) with Radiographic Occult Molecular Residual Disease Treated with Botensilimab (AGEN1181; Bot) plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)